EBITDA Margin % is calculated as EBITDA divided by its Revenue. Insmed's EBITDA for the
three
months ended in Mar. 2026 was MXN-2,495 Mil. Insmed's Revenue for the
three
months ended in Mar. 2026 was MXN5,517 Mil. Therefore, Insmed's EBITDA margin for the quarter that ended in Mar. 2026 was -45.23%.
Insmed (MEX:INSM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Insmed EBITDA Margin % Related Terms
Insmed EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Insmed's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INSM vs INCY, BNTX, ROIV: EBITDA Margin % Comparison
For the Biotechnology subindustry, Insmed's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Insmed's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Insmed's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed (MEX:INSM) has a EBITDA Margin % of -45.23% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Insmed and its competitors. According to the industry distribution chart, Insmed ranks #532 out of 938 companies in the Biotechnology industry, placing it in the top 56.7%.
Is Insmed's EBITDA Margin % too high?
Insmed's current EBITDA Margin % is -45.23%. Based on the distribution chart, Insmed ranks #532 out of 938 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's EBITDA Margin % compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #532 out of 938 companies for EBITDA Margin %. This places Insmed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Insmed and its competitors. Insmed's current EBITDA Margin % is -45.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current EBITDA Margin % of -45.23%. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current EBITDA Margin % is -45.23%. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Insmed (MEX:INSM), the current EBITDA Margin % is -45.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.
Key valuation signals for MEX:INSM:
EBITDA Margin %: -45.23%
GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score
Get the complete analysis for MEX:INSM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
